The anti-EBV IgA ELISA, is an enzyme linked immunosorbent assay intended for the detection and quantitative determination of human IgA to the early antigen and nuclear antigen of the Epstein-Barr virus contained
in human serum.
Epstein-Barr virus (EBV), a human herpes virus, is the cause of a major etiological factor in a number of human diseases, including infectious mononucleosis, Burkitt’s lymphoma and nasopharyngeal carcinoma. Nasopharyngeal carcinoma (NPC) is a malignant tumor which occurs at high frequency among Chinese living in Taiwan, Hong Kong, Singapore, Malaysia and South China. It has poor prognosis due to that majority of cases is at late stage of the disease and therefore diagnosis of NPC at early stage would be important to reduce the mortality.
Seroepidemiological data have shown that sera from NPC patients have high titers of EBV specific antibodies. A rise in titer of serum IgA to EBV viral capsid antigen (VCA) and EBV induced early antigen (EA) in patients with NPC was first reported by Henle and Henle (1976). IgA and IgG to EBV membrane antigen (MA) have also been detected in sera from NPC patients (Zhu et al., 1986). Although IgA responses to VCA measured in immunofluorescent assays have generally been used to screen for NPC, the studies indicate that the IgA against EA combined with EB Nuclear Antigen-1 (EBNA-1) as measured by ELISA showed better specificity and sensitivity than the IgA responses to VCA as measured by immunofluorescence (Fones-Tan et al., 1994). A soluble form of the EBV EA+EBNA-1 is the basis of the serology assay being described in this instruction manual.
If you are interested in this product, please contact us by Biomed @youlum.com.tw.